论文部分内容阅读
目的观察早期糖尿病视网膜病变药物治疗后的视野变化。方法选择42例84眼血糖控制稳定,糖化血红蛋白A1测定正常的早期糖尿病视网膜病变患者,给予迈之灵和弥可保片口服6个月。在半暗室条件下,应用瑞士产Octpus101型视野计分别在治疗前、治疗后3个月和6个月测试平均缺陷、丢失方差、刺激丢失方差和可靠性因素,并进行配对t检验。结果上述各指标治疗后3个月与治疗前比较无明显变化,治疗后6个月与治疗前比较有显著性差异,治疗后6个月与治疗后3个月比较有显著性差异。结论迈之灵和弥可保片联合应用能改善早期糖尿病视网膜病变患者的视野,是一种有效的治疗方法。
Objective To observe the visual field changes of patients with early diabetic retinopathy after drug treatment. Methods 42 patients (84 eyes) with stable control of blood glucose and normal control of glycated hemoglobin (A1) were enrolled in this study. Maizarin and Miocao tablets were given orally for 6 months. In semi-dark room conditions, the Swiss-made Octpus101-type visual field instrument was used to test the mean defect, loss variance, variance of loss of stimulus, and reliability before treatment, 3 months and 6 months after treatment, and paired t-test. Results There was no significant change in each index above 3 months after treatment compared with that before treatment. There was a significant difference between 6 months after treatment and before treatment. There was significant difference between 6 months after treatment and 3 months after treatment. Conclusion The combination of maizilin and Mi Kebao can improve the vision of patients with early diabetic retinopathy and is an effective treatment.